Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13840013 | 0.94 | TDP1 (0.44) | CYP3A4TDP1ESR1ESR2LMNA | |
| SCHEMBL2085135 | 0.66 | TDP1 (1.00) | CYP3A4TDP1ESR1ESR2LMNA | |
| SCHEMBL5028587 | 0.66 | TDP1 (1.00) | CYP3A4TDP1ESR1ESR2LMNA | |
| SCHEMBL101 | 0.66 | TDP1 (1.00) | CYP3A4TDP1ESR1ESR2LMNA | |
| Benzene SCHEMBL6890099 | 0.66 | TDP1 (1.00) | CYP3A4TDP1ESR1ESR2LMNA | |
| SCHEMBL5076059 | 0.65 | TDP1 (0.80) | CYP3A4TDP1ESR1ESR2LMNA | |
| SCHEMBL25384985 | 0.64 | TDP1 (0.92) | CYP3A4TDP1ESR1ESR2LMNA | |
| SCHEMBL22558063 | 0.64 | TDP1 (0.92) | CYP3A4TDP1ESR1ESR2LMNA | |
| SCHEMBL1195618 | 0.64 | TDP1 (0.92) | CYP3A4TDP1ESR1ESR2LMNA | |
| SCHEMBL20582981 | 0.64 | TDP1 (0.92) | CYP3A4TDP1ESR1ESR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858334-B2 | Method for aerobic oxidative coupling of thiophenes with a ligand-supported palladium catalyst | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190210993-A1 | Method for Aerobic Oxidative Coupling of Thiophenes with a Ligand-Supported Palladium Catalyst | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858334-B2 | Method for aerobic oxidative coupling of thiophenes with a ligand-supported palladium catalyst | PPOX, TST, COX6C | CYP3A4 164/4885TDP1 1835/4885ESR1 2454/4885 |
| US-20190210993-A1 | Method for Aerobic Oxidative Coupling of Thiophenes with a Ligand-Supported Palladium Catalyst | PPOX, TST, COX6C | CYP3A4 164/4885TDP1 1835/4885ESR1 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.